Listing of the claims

This listing of claims provided below will replace all prior versions.

- 1. (cancelled)
- 2. (currently amended) A method of inhibiting the binding of a p56^{lck} molecule via an SH2 domain thereof to a corresponding cellular binding protein, or inhibiting the activity of a p56^{lck} molecule via an SH2 domain thereof, comprising administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt thereof

$$\frac{\left(Z_{3}\right)_{n} \quad \left(Z_{1}\right)_{n}}{\left(Z_{2}\right)_{n} \quad B \quad A \quad A \quad D \quad \left(Z_{2}\right)_{n}} \tag{I)}$$

wherein,

B- is a phenyl ring,

D is a phenyl ring,

- A-- is, in each case independently of each other, a 5-membered saturated or partially or fully unsaturated heterocyclic ring-containing 1 or 2 heteroatoms selected from O, S, and N,
- Q is a bond or an alkylene or alkenylene group containing 1-5 carbon atoms, which is optionally substituted with =O, and in which optionally a carbon atom is replaced with an N atom,
- Z₁ is, in each case independently, =O, =NH, or alkyl containing 1 to 5 carbon atoms,
- Z₂—is, in each case independently, halogen, alkyl containing 1-5 carbon atoms, or CO₂H,
- Z₃— is, in each case independently, alkyl-containing 1-5 carbon-atoms, and
- n is, in each case independently, 0, 1, 2, or 3, wherein the compounds or a pharmaceutically acceptable salt thereof that is administered is selected from the group consisting of:

Application No.: 10/582,640

3. (cancelled)

- 4. (withdrawn/currently amended) A method of <u>claim 2</u> <u>elaim 1</u>, wherein immunosuppression is affected.
- 5. (withdrawn/currently amended) A method of <u>claim 2</u> elaim 1, wherein said patient suffers from an autoimmune disease or from transplant rejection.
- 6. (withdrawn) A method of claim 5, wherein said patient suffers from rheumatoid arthritis.
- 7. (currently amended) A method of claim 2 claim 1, wherein said patient suffers from a

neoplasm or a hyperplasia.

- 8. (original) A method of claim 7, wherein said patient suffers from a benign or malignant tumor.
- 9. (withdrawn/currently amended) A method of <u>claim 2</u> claim 1, wherein said patient suffers from a depressed immune system.
- 10. (currently amended) A method of <u>claim 2 elaim-1</u>, wherein said patient suffers from leukemia, lymphoma, ovarian cancer <u>or</u> breast cancer.
- 11. (currently amended) A method of claim 2 claim 1, wherein said patient is human.
- 12-14. (cancelled)
- 15. (withdrawn/currently amended) A method of <u>claim 2 elaim 12</u>, wherein the compound <u>of number</u> 73 or 92 or a pharmaceutically acceptable salt thereof is administered.
- 16-18. (cancelled)
- 19. (currently amended) A method of claim 2, wherein the compound of formula I has a solubility such that the ClogP value is ≤ 5 , a molecular weight of ≤ 500 Daltons, and ≤ 10 hydrogen bond donors and acceptors.
- 20-22. (cancelled)
- 23. (withdrawn) A pharmaceutical composition according to claim 3 comprising a compound of formula I to IX or a pharmaceutically acceptable salt thereof.

Page 5

24. (currently amended) A method of <u>claim 2</u> elaim 1, wherein the compound is

25. (currently amended) A method of claim 2, claim 1 wherein the compound is

26. (new) A method of claim 2, wherein the compound is